Pharmacogenetic aspects of oral hypoglycemic therapy. Response and failure phenotypes
The research work attempted to answer the question whether an effective personalized glucose-lowering therapy, particularly with metformin, is possible in patients with type 2 diabetes based on single nucleotide polymorphism of the three genes (endothelial nitric oxide synthase, 8-oxoguanine DNA gly...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Remedium Group LLC
2015-12-01
|
| Series: | Медицинский совет |
| Subjects: | |
| Online Access: | https://www.med-sovet.pro/jour/article/view/233 |
| id |
doaj-f090df157ad043788d765230e725f657 |
|---|---|
| record_format |
Article |
| spelling |
doaj-f090df157ad043788d765230e725f6572021-07-28T13:29:21ZrusRemedium Group LLCМедицинский совет2079-701X2658-57902015-12-0108828510.21518/2079-701X-2015-8-82-85233Pharmacogenetic aspects of oral hypoglycemic therapy. Response and failure phenotypesY. A. Sorokina0Nizhniy Novgorod State Medical Academy, Russia's Ministry of HealthThe research work attempted to answer the question whether an effective personalized glucose-lowering therapy, particularly with metformin, is possible in patients with type 2 diabetes based on single nucleotide polymorphism of the three genes (endothelial nitric oxide synthase, 8-oxoguanine DNA glycosylase and p53). Metformin efficacy could depend, in particular, on the presence of polymorphism in these genes.https://www.med-sovet.pro/jour/article/view/233фармакогенетикаметформин фенотип «провала»фенотип «ответа»персонифицированная медицинаpharmacogeneticsmetforminfailure phenotyperesponse phenotypepersonalized medicine |
| collection |
DOAJ |
| language |
Russian |
| format |
Article |
| sources |
DOAJ |
| author |
Y. A. Sorokina |
| spellingShingle |
Y. A. Sorokina Pharmacogenetic aspects of oral hypoglycemic therapy. Response and failure phenotypes Медицинский совет фармакогенетика метформин фенотип «провала» фенотип «ответа» персонифицированная медицина pharmacogenetics metformin failure phenotype response phenotype personalized medicine |
| author_facet |
Y. A. Sorokina |
| author_sort |
Y. A. Sorokina |
| title |
Pharmacogenetic aspects of oral hypoglycemic therapy. Response and failure phenotypes |
| title_short |
Pharmacogenetic aspects of oral hypoglycemic therapy. Response and failure phenotypes |
| title_full |
Pharmacogenetic aspects of oral hypoglycemic therapy. Response and failure phenotypes |
| title_fullStr |
Pharmacogenetic aspects of oral hypoglycemic therapy. Response and failure phenotypes |
| title_full_unstemmed |
Pharmacogenetic aspects of oral hypoglycemic therapy. Response and failure phenotypes |
| title_sort |
pharmacogenetic aspects of oral hypoglycemic therapy. response and failure phenotypes |
| publisher |
Remedium Group LLC |
| series |
Медицинский совет |
| issn |
2079-701X 2658-5790 |
| publishDate |
2015-12-01 |
| description |
The research work attempted to answer the question whether an effective personalized glucose-lowering therapy, particularly with metformin, is possible in patients with type 2 diabetes based on single nucleotide polymorphism of the three genes (endothelial nitric oxide synthase, 8-oxoguanine DNA glycosylase and p53). Metformin efficacy could depend, in particular, on the presence of polymorphism in these genes. |
| topic |
фармакогенетика метформин фенотип «провала» фенотип «ответа» персонифицированная медицина pharmacogenetics metformin failure phenotype response phenotype personalized medicine |
| url |
https://www.med-sovet.pro/jour/article/view/233 |
| work_keys_str_mv |
AT yasorokina pharmacogeneticaspectsoforalhypoglycemictherapyresponseandfailurephenotypes |
| _version_ |
1721274549205467136 |